Evidence map›Paper›PMID 30015966›Full record

ArticleOncology reports2018

DMBA promotes ErbB2‑mediated carcinogenesis via ErbB2 and estrogen receptor pathway activation and genomic instability.

Zhikun Ma, Young Mi Kim, Erin W Howard, Xiaoshan Feng, Stanley D Kosanke, Shihe Yang, Yunbo Jiang, Amanda B Parris, Xia Cao, Shibo Li and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 23 citations in OpenAlex.

  1. Frontiers in pharmacology · 2026
    Article
  2. Article
  3. Heliyon · 2024
    Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Zhikun MaDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Young Mi KimDepartment of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma, OK 73104, USA.
Erin W HowardJulius L. Chambers Biomedical/Biotechnology Research Institute, Department of Biological and Biomedical Sciences, North Carolina Central University, North Carolina Research Campus, Kannapolis, NC 28081, USA.
Xiaoshan FengDepartment of Oncology, First Affiliated Hospital of Henan University of Sciences and Technology, Luoyang, Henan 471500, P.R. China.
Stanley D KosankeDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Shihe YangDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Yunbo JiangDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Amanda B ParrisJulius L. Chambers Biomedical/Biotechnology Research Institute, Department of Biological and Biomedical Sciences, North Carolina Central University, North Carolina Research Campus, Kannapolis, NC 28081, USA.
Xia CaoJulius L. Chambers Biomedical/Biotechnology Research Institute, Department of Biological and Biomedical Sciences, North Carolina Central University, North Carolina Research Campus, Kannapolis, NC 28081, USA.
Shibo LiDepartment of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma, OK 73104, USA.
Xiaohe YangDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
University of Oklahoma Health Sciences Center · USNorth Carolina Central University · USFirst Affiliated Hospital of Henan University of Science and Technology · CN

Funding

Mechanisms of in utero exposure to bisphenol A induced mammary tumor riskR21ES025337 · NIEHS · NORTH CAROLINA CENTRAL UNIVERSITY · PI YANG, XIAOHE · 2015 to 2016
$410k
6 · The paper itself

Abstract

Environmental factors, including 7,12‑dimethylbenz[a]anthracene (DMBA) exposure, and genetic predisposition, including ErbB2 overexpression/amplification, have been demonstrated to increase breast cancer susceptibility. Although DMBA‑ and ErbB2‑mediated breast cancers are well‑studied in their respective models, key interactions between environmental and genetic factors on breast cancer risk remain unclear. Therefore, the present study aimed to investigate the effect of DMBA exposure on ErbB2‑mediated mammary tumorigenesis. MMTV‑ErbB2 transgenic mice exposed to DMBA (1 mg) via weekly oral gavage for 6 weeks exhibited significantly enhanced mammary tumor development, as indicated by reduced tumor latency and increased tumor multiplicity compared with control mice. Whole mount analysis of premalignant mammary tissues from 15‑week‑old mice revealed increased ductal elongation and proliferative index in DMBA‑exposed mice. Molecular analyses of premalignant mammary tissues further indicated that DMBA exposure enhanced epidermal growth factor receptor (EGFR)/ErbB2 and estrogen receptor (ER) signaling, which was associated with increased mRNA levels of EGFR/ErbB2 family members and ER‑targeted genes. Furthermore, analysis of tumor karyotypes revealed that DMBA‑exposed tumors displayed more chromosomal alterations compared with control tumors, implicating DMBA‑induced chromosomal instability in tumor promotion in this model. Together, the data suggested that DMBA‑induced deregulation of EGFR/ErbB2‑ER pathways plays a critical role in the enhanced chromosomal instability and promotion of ErbB2‑mediated mammary tumorigenesis. The study highlighted gene‑environment interactions that may increase risk of breast cancer, which is a critical clinical issue.

Indexed as

Genomic Instability9,10-Dimethyl-1,2-benzanthraceneAnimalsApoptosisCarcinogensCell ProliferationCell Transformation, NeoplasticErb-b2 Receptor Tyrosine KinasesFemaleMammary Neoplasms, ExperimentalMiceMice, TransgenicReceptors, EstrogenTumor Cells, Cultured9,10-Dimethyl-1,2-benzanthraceneCarcinogensErbb2 protein, mouseErb-b2 Receptor Tyrosine KinasesReceptors, Estrogen

Identifiers

PMID30015966
PMCPMC6072406
OpenAlexW2810298711

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.